Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation

Keyphrases

• Phase II Trial 100%
• Monotherapy 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• EGFR mutation 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Gefitinib 100%
• Overall Survival 50%
• Chemotherapy 50%
• Epidermal Growth Factor Receptor 50%
• Lung Cancer 50%
• Advanced Disease 50%
• Long-term Prognosis 50%
• Lung Cancer Treatment 50%
• Tyrosine Kinase 50%
• Clinical Efficacy 50%
• Cancer Causes 50%
• Cancer Mortality 50%
• Chemotherapy-naïve Patients 50%
• Small Molecule Targeting 50%
• Pretreated Patients 50%
• Lung Cancer Symptoms 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 100%
• Lung Cancer 100%
• Gefitinib 100%
• Disease 33%
• Monotherapy 33%
• Chemotherapy 33%
• Malignant Neoplasm 16%
• Symptom 16%
• Overall Survival 16%
• Protein Tyrosine Kinase 16%